Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Anika Therapeutics Inc

ANIK ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$21.50

▲ +1.56%

Market Cap $287.73M · Vol 49.94K

Key Metrics

P/E Ratio

N/A

FWD: 81.26

Market Cap

$287.73M

Micro Cap

Div Yield

N/A

EPS Growth

+98.68%

YoY

RSI (14)

75.37

Momentum

Beta

0.22

vs Market

52W High

$22.28

3.50% below

52W Low

$8.29

159.35% above

Volume

49.94K

Avg 38.74K

P/B

0.93

Price-to-book

ROE

N/A

Return on equity

Free Float

93.60%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Anika Therapeutics Inc (ANIK) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ANIK pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.37%

+38.53%

+40.16%

+110.58%

YTD

+123.73%

+148.84%

+16.22%

-48.61%

Financials & Valuation

TTM · Annual

Total Revenue	$112.82M
Net Income	$-9,979,000.00
Revenue Growth (YoY)	+15.56%
Gross Margin	56.56%
Operating Margin	-9.80%
Net Profit Margin	-8.85%
ROE	N/A
ROA · ROIC	-4.74% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	81.26
PEG Ratio	N/A
P/S	1.22
P/B	0.93
P/FCF	31.59
EPS Growth	+98.68%
Outstanding Shares	13.38M

Technical Indicators

50-Day SMA	$16.37
200-Day SMA	$13.09
RSI (14)	75.37
Beta	0.22
52-Week High	$22.28
52-Week Low	$8.29

Volume Today	49.94K
Avg Daily Volume (30D)	38.74K
Relative Volume	1.29x
Volatility (10D)	68.76
Volatility (30D)	61.11
Free Float	93.60%

Analyst Consensus

STRONG BUY

Current Price $21.50

Mean Target $21.00

52W Low$8.29 52W High$22.28

Current

Target

$8.29 $22.28

Current Analyst target

-2.33% downside risk · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S609X7

ISINUS0352551081

CountryUnited States of America

Sub-IndustryMedical Equipment, Supplies & Distribution (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

ABT Abbott Laboratories -0.02% MDT Medtronic PLC +0.76% COR Cencora Inc +1.23% 7741.T Hoya Corp +0.32% BDX Becton Dickinson and Co +0.79%

Company Profile

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.